BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31645346)

  • 1. Novel
    Hassan M; Butler E; Wilson R; Roy A; Zheng Y; Liem P; Rakheja D; Pavlick D; Young LL; Rosenzweig M; Erlich R; Ali SM; Leavey PJ; Parsons DW; Skapek SX; Laetsch TW
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
    Arts FA; Chand D; Pecquet C; Velghe AI; Constantinescu S; Hallberg B; Demoulin JB
    Oncogene; 2016 Jun; 35(25):3239-48. PubMed ID: 26455322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.
    Arts FA; Sciot R; Brichard B; Renard M; de Rocca Serra A; Dachy G; Noël LA; Velghe AI; Galant C; Debiec-Rychter M; Van Damme A; Vikkula M; Helaers R; Limaye N; Poirel HA; Demoulin JB
    Hum Mol Genet; 2017 May; 26(10):1801-1810. PubMed ID: 28334876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
    Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
    BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.
    Pond D; Arts FA; Mendelsohn NJ; Demoulin JB; Scharer G; Messinger Y
    Genet Med; 2018 Jan; 20(1):142-150. PubMed ID: 28726812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.
    Hettmer S; Dachy G; Seitz G; Agaimy A; Duncan C; Jongmans M; Hirsch S; Kventsel I; Kordes U; de Krijger RR; Metzler M; Michaeli O; Nemes K; Poluha A; Ripperger T; Russo A; Smetsers S; Sparber-Sauer M; Stutz E; Bourdeaut F; Kratz CP; Demoulin JB
    Fam Cancer; 2021 Oct; 20(4):327-336. PubMed ID: 32888134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a
    Sramek M; Neradil J; Macigova P; Mudry P; Polaskova K; Slaby O; Noskova H; Sterba J; Veselska R
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infantile Myofibromatosis With Intracranial Extradural Involvement and PDGFRB Mutation: A Case Report and Review of the Literature.
    Al Qawahmed R; Sawyer SL; Vassilyadi M; Qin W; Boycott KM; Michaud J
    Pediatr Dev Pathol; 2019; 22(3):258-264. PubMed ID: 30103666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
    Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
    Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.
    Weller JM; Keil VC; Gielen GH; Herrlinger U; Schäfer N
    Am J Med Genet A; 2019 Sep; 179(9):1895-1897. PubMed ID: 31291054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recurrent PDGFRB mutation causes familial infantile myofibromatosis.
    Cheung YH; Gayden T; Campeau PM; LeDuc CA; Russo D; Nguyen VH; Guo J; Qi M; Guan Y; Albrecht S; Moroz B; Eldin KW; Lu JT; Schwartzentruber J; Malkin D; Berghuis AM; Emil S; Gibbs RA; Burk DL; Vanstone M; Lee BH; Orchard D; Boycott KM; Chung WK; Jabado N
    Am J Hum Genet; 2013 Jun; 92(6):996-1000. PubMed ID: 23731537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
    Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
    Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence.
    Murray N; Hanna B; Graf N; Fu H; Mylène V; Campeau PM; Ronan A
    Eur J Med Genet; 2017 Jul; 60(7):353-358. PubMed ID: 28286173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?
    Linhares ND; Freire MC; Cardenas RG; Bahia M; Puzenat E; Aubin F; Pena SD
    Genet Mol Res; 2014 Aug; 13(3):6287-92. PubMed ID: 25158255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.
    Martignetti JA; Tian L; Li D; Ramirez MC; Camacho-Vanegas O; Camacho SC; Guo Y; Zand DJ; Bernstein AM; Masur SK; Kim CE; Otieno FG; Hou C; Abdel-Magid N; Tweddale B; Metry D; Fournet JC; Papp E; McPherson EW; Zabel C; Vaksmann G; Morisot C; Keating B; Sleiman PM; Cleveland JA; Everman DB; Zackai E; Hakonarson H
    Am J Hum Genet; 2013 Jun; 92(6):1001-7. PubMed ID: 23731542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
    Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
    J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal Infantile Myofibromatosis Caused by Novel Activating Imatinib-Responsive Variants in
    Howaldt A; Lenglez S; Velmans C; Schultheis AM; Clahsen T; Matthaei M; Kohlhase J; Vokuhl C; Büttner R; Netzer C; Demoulin JB; Cursiefen C
    Ophthalmol Sci; 2024; 4(3):100444. PubMed ID: 38374928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis.
    Guimier A; Gordon CT; Hully M; Blauwblomme T; Minard-Colin V; Bole-Feysot C; Nitschké P; Oufadem M; Boddaert N; Sarnacki S; Amiel J
    Am J Med Genet A; 2019 Jul; 179(7):1304-1309. PubMed ID: 31004414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Oncogenic
    Elsbernd A; Boulouadnine B; Ahmed A; Farooqi M; Sandritter T; Shakhnovich V; Blanding D; Demoulin JB; Thompson J
    JCO Precis Oncol; 2022 Oct; 6():e2200250. PubMed ID: 36201717
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
    Dereure O
    Ann Dermatol Venereol; 2017; 144(8-9):574-575. PubMed ID: 28756885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.